3-(4-{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}butyl)-5-(4-isopropoxyphenyl)-5-methylimidazolidine-2,4-dione | 1192758-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(4-{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}butyl)-5-(4-isopropoxyphenyl)-5-methylimidazolidine-2,4-dione
• 英文别名: 3-[4-[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]butyl]-5-methyl-5-(4-propan-2-yloxyphenyl)imidazolidine-2,4-dione
• CAS: 1192758-10-3
• 化学式: C₄₀H₃₈F₃N₃O₄
• 分子量: 681.755
• InChiKey: FLRHHKLIGPKXIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  50
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• QUINOLINE COMPOUNDS
  申请人：KOURA Minoru

  公开号：US20100016327A1

  公开（公告）日：2010-01-21

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎症性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。通过以下一般式（1）表示的喹啉化合物或其盐，或它们的溶剂化合物。
• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：EP3402477A2

  公开（公告）日：2018-11-21
• US8008306B2
  申请人：——

  公开号：US8008306B2

  公开（公告）日：2011-08-30
• [EN] TREATMENT AND DIAGNOSIS OF CANCER<br/>[FR] TRAITEMENT ET DIAGNOSTIC DU CANCER
  申请人：RGENIX INC

  公开号：WO2016100619A2

  公开（公告）日：2016-06-23

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• [EN] METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS<br/>[FR] MÉTHODES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À DES CELLULES SUPPRESSIVES DÉRIVÉES DE CELLULES MYÉLOÏDES
  申请人：UNIV ROCKEFELLER

  公开号：WO2017123568A2

  公开（公告）日：2017-07-20

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.